Table 6 TSQM domain and global scores: ANCOVA analyses
From: The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
TSQM scale | ANOVA | ANCOVAa | ||||
|---|---|---|---|---|---|---|
LS meanb | 95 % CI | p valuec | LS meanb | 95 % CI | p valuec | |
Effectiveness | ||||||
CF | 65.2 | 59.9, 70.5 | 65.0 | 59.6, 70.5 | ||
CDMF | 66.1 | 62.5, 69.8 | 66.2 | 62.5, 70.0 | ||
Difference | −0.9 | −7.4, 5.5 | 0.776 | −1.2 | −7.9, 5.4 | 0.720 |
Convenience | ||||||
CF | 94.4 | 90.6, 98.3 | 94.8 | 90.9, 98.6 | ||
CDMF | 86.8 | 84.2, 89.4 | 86.7 | 84.1, 89.3 | ||
Difference | 7.6 | 3.0, 12.3 | 0.001 | 8.1 | 3.4, 12.8 | <0.001 |
Side effects | ||||||
CF | 91.6 | 85.6, 97.5 | 91.3 | 85.3, 97.3 | ||
CDMF | 81.6 | 77.8, 85.5 | 81.8 | 77.9, 85.6 | ||
Difference | 10.0 | 2.8, 17.1 | 0.007 | 9.5 | 2.3, 16.8 | 0.010 |
Global | ||||||
CF | 76.0 | 70.2, 81.8 | 75.5 | 69.7, 81.4 | ||
CDMF | 68.8 | 64.8, 72.8 | 69.0 | 65.0, 73.0 | ||
Difference | 7.2 | 0.1, 14.2 | 0.047 | 6.5 | −0.6, 13.7 | 0.076 |